Myogenic Underactive Bladder and Heart Failure Resemblance: A Novel Role for SGLT2 Inhibition?

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Faria Costa, G (Author) FMUP; Charrua A. (Author) FMUP; Carlos Silva (Author) FMUP; Leite-Moreira AF (Author) FMUP; Antunes Lopes, T (Author) Other

Journal

Title: European Urology Focus

Vol. 8 No. 1

ISSN: 2405-4569

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 3 Citations

Scopus - 3 Citations

Other information

Authenticus ID: P-00W-MY7

DOI: 10.1016/j.euf.2022.04.016

Abstract (EN): The heart and bladder share physiological biomechanical determinants of contraction. Heart failure (HF) and myogenic underactive bladder (mUAB) also share similarities in their pathophysiology. In both cases there is muscle injury that is directly linked to disease stage. In the final stage, both myocardium and detrusor show marked fibrosis and lower contractility. While HF has an established pharmacological treatment, there are still no effective drugs for mUAB. This mini-review explores the similarities between HF and mUAB and suggests that, as in HF, SGLT2 inhibitors may also have a beneficial role in mUAB. Patient summary: To date, there is no treatment for underactive bladder caused by problems with the bladder muscle (mUAB). We review similarities between this condition and heart failure and hypothesize that a recent drug class with striking results in heart failure might also have a beneficial role in mUAB.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 4